Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO

BEIJING - A New York-headquartered money management outfit that is the largest shareholder in Charles River Laboratories International has unexpectedly thrown up a potential blockade in the drug research firm's $1.6 billion proposal to acquire China's WuXi PharmaTech